YTHDF2-IN-1
Based on 1 Customer Validation
YTHDF2-IN-1 (Compound CK-75) is a selective YTHDF2 inhibitor (Kd = 26.2 μM). YTHDF2-IN-1 binds to a small hydrophobic pocket on the YTH domain of YTHDF2, disrupting the interaction between YTHDF2 and m6A-modified RNA. YTHDF2-IN-1 induces cell cycle arrest and Apoptosis. YTHDF2-IN-1 is applicable to research on chronic myeloid leukemia, colon cancer and choriocarcinoma.
For research use only. We do not sell to patients.
- Purity : 99.42%
- Formula: C21H14N2O4
- Molecular Weight:358.35
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
[1]|
YTHDF2 26.2 μM (Kd) |
In Vitro
YTHDF2-IN-1 (100 μM; 30 min) inhibits the interaction between the purified YTHDF2 YTH domain and m6A RNA in FP assays, with an inhibition rate of 82.3% at a concentration of 100 μM[1].
YTHDF2-IN-1 binds to the purified YTH domain of YTHDF2 in MST assays, with a Kd value of 26.2 μM[1].
YTHDF2-IN-1 (10-25 μM; 24 h) induces concentration-dependent G0/G1 cell cycle arrest in K562 cells[1].
YTHDF2-IN-1 (25-100 μM; 24 h) induces concentration-dependent apoptosis in K562 cells[1].
YTHDF2-IN-1 (0.4-100 μM; 72 h) exhibits micromolar cytotoxicity against K562, HCT116 and JAR cancer cells in MTT assays, with corresponding IC50 values of 29.7 μM, 33.3 μM and 47.5 μM after 72 h of treatment[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:K562 human cancer cells
-
Concentration:10-25 μM
-
Incubation Time:24 h
-
Result:Caused >70% of cells to accumulate in the G0/G1 phase at 25 μM.
Induced concentration-dependent G0/G1 phase cell cycle arrest.
-
Cell Line:K562 human cancer cells
-
Concentration:25, 50, 100 μM
-
Incubation Time:24 h
-
Result:Induced total apoptosis in 28.2% of cells at 25 μM, 34.9% at 50 μM, and 45.4% at 100 μM.
Chemical Information
-
Appearance Solid
-
Molecular Weight 358.35
-
Formula C21H14N2O4
-
Color Yellow to orange
-
SMILES
O=C(O)C1=CC=C(N2N=CC(C(C3=C4C=CC=CC4=CC=C3O)=O)=C2)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 50 mg/mL (139.53 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7906 mL | 13.9528 mL | 27.9057 mL | 69.7642 mL |
| 5 mM | 0.5581 mL | 2.7906 mL | 5.5811 mL | 13.9528 mL | |
| 10 mM | 0.2791 mL | 1.3953 mL | 2.7906 mL | 6.9764 mL | |
| 15 mM | 0.1860 mL | 0.9302 mL | 1.8604 mL | 4.6509 mL | |
| 20 mM | 0.1395 mL | 0.6976 mL | 1.3953 mL | 3.4882 mL | |
| 25 mM | 0.1116 mL | 0.5581 mL | 1.1162 mL | 2.7906 mL | |
| 30 mM | 0.0930 mL | 0.4651 mL | 0.9302 mL | 2.3255 mL | |
| 40 mM | 0.0698 mL | 0.3488 mL | 0.6976 mL | 1.7441 mL | |
| 50 mM | 0.0558 mL | 0.2791 mL | 0.5581 mL | 1.3953 mL | |
| 60 mM | 0.0465 mL | 0.2325 mL | 0.4651 mL | 1.1627 mL | |
| 80 mM | 0.0349 mL | 0.1744 mL | 0.3488 mL | 0.8721 mL | |
| 100 mM | 0.0279 mL | 0.1395 mL | 0.2791 mL | 0.6976 mL |